NYSE:GM charts & data provided by TradingView

Latest Insights on GM

Whatever your market plans, remember that Great Stuff is never gonna give you up, never gonna let you down … we’ll never run around or desert you! China’s Potential Doom; INO’s Biotech Boom February 14, 2020 by Joseph Hargett 2020 Financial Crisis, Great Stuff Friday Four Play: The “Never Gonna Give You Up” Edition Happy Valentine’s Day, dear readers! I don’t have chocolates, roses or even dinner reservations (I know, I’m a horrible date today). But I do have market data and stock gains for Great Stuff readers. Let’s start with the good news. U.S. retail sales rose for […]
The market’s got chills. They’re multiplying. And China’s losing control. Because the Wuhan virus they’re supplying … is electrifying! Alibaba Explains It All; Tesla’s $2 Billion Call February 13, 2020 by Joseph Hargett Great Stuff Alibaba Explains It All The market’s got chills. They’re multiplying. And China’s losing control. Because the Wuhan virus they’re supplying … is electrifying! Yesterday’s lull in new, reported coronavirus infections was the calm before the storm. Today, China announced 15,152 new cases and 254 new deaths. The totals now stand at more than 60,0000 confirmed […]
There’s a new version of the Dogs of the Dow strategy, and it’s an even better way to beat the market. Buy 10 “Small Dog” Stocks to CRUSH the Market February 7, 2020 by Ian King Stocks, Trading Strategies, Winning Investor Daily There’s a new version of the Dogs of the Dow strategy, and it’s an even better way to beat the market.
If you don’t think the Wuhan coronavirus outbreak will impact the U.S. economy, I’ve got some bad news for you. The Chinese Time Bomb; Tesla Tendies Time February 4, 2020 by Joseph Hargett Great Stuff The Ticking Chinese Time Bomb Sorry to ruin your bull market party, but there’s an issue we need to discuss … like, right now. I’m talking about the Wuhan coronavirus and the U.S.-China “phase 1” trade deal. Here’s the thing: More than 20,000 Chinese are infected with the Wuhan virus, with some 427 dead. Tens […]
abbvie stock Profit From AbbVie’s Struggles Today February 4, 2020 by Chad Shoop American Investor Today, Stocks Abbvie’s flagship medication Humira is a huge seller in the U.S. and abroad. But as more companies develop their own versions, will Abbvie’s stock crater in the face of tighter competition? I’ll review Abbvie’s balance sheet and fundamentals to let you know whether you should expect the stock to surge — or fall even further in 2020.

Newsletter Sign Up

Sponsored

CS Care Video

MEET OUR EXPERTS

WHAT READERS ARE SAYING..

“Loving this. Should have started a long time ago.”

- Jay

"You told me to ignore the noise on Wall Street. And thanks to you, I started towards the end of 2016 with $200,000 in my account and I recently put in an extra $100,000. [As of February 2019] My account is worth $500,788! I would’ve missed out if I followed conventional wisdom."

- Helen C.

"Since I started following your secret over your multiple publications, my $659,000 account is up to $715,000 in just 2 months. I’m up $56,000 in one month alone."

- Will O.

Share This